AAN: Monoclonal Antibodies for MS During Breastfeeding Not Harmful
By Elana Gotkine HealthDay Reporter
TUESDAY, March 12, 2024 -- For mothers with multiple sclerosis or neuromyelitis optica spectrum disease, receipt of monoclonal antibodies (mAb) during breastfeeding is not associated with infant hospitalization, systemic antibiotic use, developmental delay, or weight at follow-up, according to a study scheduled for presentation at the annual meeting of the American Academy of Neurology, to be held from April 13 to 18 in Denver.
Laura Witt, from St. Joseph Hospital at Ruhr University in Bochum, Germany, and colleagues examined infant development during the first 36 months of life for infants of mothers receiving mAb for multiple sclerosis. A total of 183 mAb breastfed-exposed infants whose mothers had a diagnosis of multiple sclerosis or neuromyelitis optica spectrum disease were compared to 183 unexposed infants (controls). mAb exposure during breastfeeding started on a median of 19 days postpartum.
Breastfeeding participants most often received natalizumab, followed by ocrelizumab, rituximab, and ofatumumab (68.31, 18.58, 6.01, and 5.46 percent, respectively); while breastfeeding, two cases switched from natalizumab to ocrelizumab and one from rituximab to ocrelizumab. The researchers found that annual infant hospitalization, annual systemic antibiotic use, developmental delay, or weight at follow-up visits were not associated with mAb-exposed breastfeeding.
"Our data show infants exposed to these medications through breastfeeding experienced no negative effects on health or development within the first three years of life," coauthor Kerstin Hellwig, M.D., also from St. Joseph Hospital, said in a statement.
The study was partly funded by pharmaceutical companies.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
COVID-19 Vaccination Not Tied to Adverse Pregnancy Outcomes
TUESDAY, June 25, 2024 -- mRNA COVID-19 vaccination during pregnancy is not associated with an increased risk of adverse pregnancy outcomes, according to a study published in the...
NT-proBNP, IL-1RL Can Identify High-Risk Congenital Heart Disease in Neonates
MONDAY, June 24, 2024 -- Automated quantitative tests for NT-proBNP and interleukin 1 receptor-like 1 (IL-1 RL1) can identify high-risk congenital heart disease (CHD) in newborns...
Maternal Distress Tied to Changes in Brain Growth of Offspring
FRIDAY, June 21, 2024 -- Regional neonatal brain volumes are associated with elevated maternal psychological distress, according to a study published online June 20 in JAMA...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.